Hear perspectives from a broad set of early-stage investors, including funds that focus exclusively on seed and Series A investments, as well as those that more selectively opt to invest in early rounds. There are myriad risks that characterize early-stage investment, including technical, clinical, regulatory, reimbursement and commercial risks. How do investors look at opportunities in today’s market and assess and balance those risks with the potential upside of transforming innovation?
This session is part of the AdvaMed Accel Leadership Seminar, a program designed for executives of early and emerging growth companies. Invitation-only event - request an invitation to attend the Accel Leadership Seminar during the registration process, or for more information contact Beth Perkins at email@example.com.